Lurasidone suppresses rapid eye movement sleep and improves sleep quality in rats

Journal of Pharmacological Sciences

Volumn 126, Issue 2, 2014, Pages 164-167

  Murai, Takeshi ^a   Nakamichi, Keiko ^a   Shimizu, Isao ^a   Ikeda, Kazuhito ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Antipsychotic; Lurasidone; Sleep

Indexed keywords

LURASIDONE; SEROTONIN 2A RECEPTOR; ISOINDOLE DERIVATIVE; NEUROLEPTIC AGENT; THIAZOLE DERIVATIVE;

ADULT; ALPHA RHYTHM; ANIMAL EXPERIMENT; ARTICLE; BETA RHYTHM; CONTROLLED STUDY; DELTA RHYTHM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ELECTROENCEPHALOGRAPHY; GAMMA RHYTHM; MALE; NONHUMAN; NONREM SLEEP; OUTCOME ASSESSMENT; QUANTITATIVE FREQUENCY BAND ANALYSIS; RAT; RECEPTOR DOWN REGULATION; REM SLEEP; SLEEP DISORDER; SLEEP PATTERN; SLEEP QUALITY; SLEEP STAGE; THETA RHYTHM; WAKEFULNESS; WAVELET ANALYSIS; ANIMAL; COMPLICATION; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY; SCHIZOPHRENIA; SLEEP DISORDERS; WISTAR RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; ELECTROENCEPHALOGRAPHY; ISOINDOLES; MALE; RATS, WISTAR; SCHIZOPHRENIA; SLEEP DISORDERS; SLEEP, REM; THIAZOLES; WAKEFULNESS;

EID: 84909945947     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.14155SC     Document Type: Article

References (15)

1. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334:171-181.
2. Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther. 2011;338:605-614.
3. Horisawa T, Ishibashi T, Nishikawa H, Enomoto T, Toma S, Ishiyama T, et al. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res. 2011;220:83-906.
4. Murai T, Nakako T, Ikejiri M, Ishiyama T, Taiji M, Ikeda K. Effects of lurasidone on executive function in common marmosets. Behav Brain Res. 2013;246:125-131.
5. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as Adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, doubleblind, placebo-controlled study. Am J Psychiatry. 2013. In press.
6. Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study. Am J Psychiatry. 2013. In press.
7. Peterson MJ, Benca RM. Sleep in mood disorders. Psychiatr Clin North Am. 2006;29:1009-1032.
8. Argyropoulos S, Wilson S. Sleep disturbances in depression and the effects of antidepressants. International Review of Psychiatry. 2005;17:237-245.
9. Kluge M, Schüssler P, Steiger A. Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. Eur Neuropsychopharmacol. 2007;17:527-531.
10. Murck H, Nickel T, Künzel H, Antonijevic IA, Schill J, Zobel A, et al. State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine. Neuropsychopharmacology. 2003;28:348-358.
11. Tan X, Uchida S, Matsuura M, Nishihara K, Iguchi Y, Kojima T. Benzodiazepine effects on human sleep EEG spectra: a comparison of triazolam and flunitrazepam. Life Sci. 1998;63:675-684.
12. Bonaventure P, Dugovic C, Kramer M, De Boer P, Singh J, Wilson S, et al. Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep in major depressive disorder. J Pharmacol Exp Ther. 2012;342:429-440.
13. Morairty SR, Hedley L, Flores J, Martin R, Kilduff TS. Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats. Sleep. 2008;31:34-44.
14. Monti JM, Jantos H, Silveira R, Reyes-Parada M, Scorza C. Sleep and waking in 5,7-DHT-lesioned or (-)-pindolol-pretreated rats after administration of buspirone, ipsapirone, or gepirone. Pharmacol Biochem Behav. 1995;52:305-312.
15. Hagan JJ, Price GW, Jeffrey P, Deeks NJ, Stean T, Piper D, et al. Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br J Pharmacol. 2000;130:539-548.